Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.58 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.58 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.52 |
| ▸ | HPGDS | O60760 | 1/20 | 0.49 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.49 |
| ▸ | DHODH | Q02127 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | BCHE | P06276 | 1/20 | 0.45 |
| ▸ | ACHE | P22303 | 1/20 | 0.45 |
| ▸ | ALPL | P05186 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | CTRC | Q99895 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | EIF4E | P06730 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4496585 | 0.81 | CTRC (0.47) | POLBCTRCHPGDMEN1KMT2A | |
| SCHEMBL24122900 | 0.78 | HSP90AA1 (0.62) | HSP90AA1HSP90AB1ADORA3ALDH1A1MAPT | |
| SCHEMBL4206294 | 0.78 | HSP90AA1 (0.51) | HSP90AA1HSP90AB1ADORA3HPGDSADORA1 | |
| SCHEMBL22074307 | 0.78 | HPGDS (0.55) | ADORA3HPGDSADORA1DHODHALPL | |
| SCHEMBL21310814 | 0.77 | KDM4C (0.69) | ADORA3HPGDSKDM4EKDM4CCYP19A1 | |
| SCHEMBL29725136 | 0.77 | KDM4C (0.69) | ADORA3HPGDSKDM4EKDM4CCYP19A1 | |
| SCHEMBL21058542 | 0.76 | HSP90AA1 (0.72) | HSP90AA1HSP90AB1ADORA3ADORA1ALDH1A1 | |
| SCHEMBL7675294 | 0.76 | CTRC (0.71) | HSP90AA1HSP90AB1ADORA3ADORA1DHODH | |
| SCHEMBL27717252 | 0.75 | CTRC (0.43) | HSP90AA1HSP90AB1BCHEACHEALPL | |
| SCHEMBL2468801 | 0.75 | HSP90AA1 (0.54) | HSP90AA1HSP90AB1ADORA3HPGDSADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1917262-B1 | PIPERIDINE AND PIPERAZINE DERIVATIVES AS P2X3 ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2011-12-14 | — | — | EP | disclosed |
| US-7491821-B2 | 2-(4-fluorophenyl)-4-propyl-oxazole-5-carboxylic acid {2-[4-(6-aminopyridin-2-yl)-piperazin-1-yl]-1-methyl-ethyl}amide; purinergic receptor antagonists, analgesics; urogenital, gastointestinal and respiratory system disorders | ROCHE PALO ALTO LLC (US) | 2009-02-17 | — | — | US | disclosed |
| EP-1917262-A1 | PIPERIDINE AND PIPERAZINE DERIVATIVES AS P2X3 ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2008-05-07 | — | — | EP | disclosed |
| WO-2007020194-A1 | PIPERIDINE AND PIPERAZINE DERIVATIVES AS P2X3 ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-02-22 | — | — | WO | disclosed |
| US-20070037974-A1 | Inhibitors of P2X3 | ROCHE PALO ALTO LLC | 2007-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037974-A1 | Inhibitors of P2X3 | P2RX3, P2RX4, P2RX5 | HSP90AA1 3626/4885HSP90AB1 2971/4885ADORA3 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.